Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 10

Results For "S-1"

896 News Found

Mankind Pharma completes acquisition of Panacea Biotec’s domestic business for Rs 1872 cr
News | February 28, 2022

Mankind Pharma completes acquisition of Panacea Biotec’s domestic business for Rs 1872 cr

Mankind Pharma has agreed to retain Panacea Biotec’s sales and marketing team engaged in this business


Cabinet approves Ayushman Bharat Digital Mission at an outlay of Rs 1,600 cr.
Policy | February 27, 2022

Cabinet approves Ayushman Bharat Digital Mission at an outlay of Rs 1,600 cr.

Citizens will be able to create their ABHA (Ayushman Bharat Health Account) numbers, to which their digital health records can be linked


Zydus gets 180 days of shared exclusivity for Roflumilast tablets
Drug Approval | February 14, 2022

Zydus gets 180 days of shared exclusivity for Roflumilast tablets

The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad


Granules India Q3FY22 PAT at Rs 100.88 cr.
News | February 08, 2022

Granules India Q3FY22 PAT at Rs 100.88 cr.

Granules India has reported consolidated financial results for the period ended December 31, 2021


AsterDM Healthcare Q3FY22 PAT at Rs 148.34 cr.
News | February 08, 2022

AsterDM Healthcare Q3FY22 PAT at Rs 148.34 cr.

Aster DM Healthcare has reported consolidated financial results for the period ended December 31, 2021


Pfizer Q3FY22 PAT at Rs 143.91 crore
News | February 04, 2022

Pfizer Q3FY22 PAT at Rs 143.91 crore

The company has reported standalone financial results for the period ended December 31, 2021.


Merck donates 1.5 billionth tablet of praziquantel to Africa
Public Health | January 25, 2022

Merck donates 1.5 billionth tablet of praziquantel to Africa

The tablet donations provided for the treatment of more than 600 million schoolchildren in affected countries in sub-Saharan Africa since 2007


Biocon consolidated PAT at Rs 187.1 cr. in Q3FY22
News | January 21, 2022

Biocon consolidated PAT at Rs 187.1 cr. in Q3FY22

Biocon has reported consolidated financial results for the period ended December 31, 2021


Dr Reddy’s molnupiravir priced at Rs 1,400 for a course
News | January 04, 2022

Dr Reddy’s molnupiravir priced at Rs 1,400 for a course

Molflu is expected to be available from early next week in pharmacies throughout the country with a particular focus on states with a high caseload of Covid-19.


India’s 1st indigenously developed protein sub-unit Covid-19 vaccine Corbevax gets nod
Drug Approval | December 28, 2021

India’s 1st indigenously developed protein sub-unit Covid-19 vaccine Corbevax gets nod

It plans to deliver over 300 million doses to the Indian government